Journal of Virology · 2001 · 320 citations · 54 references
Life SciencesMolecular BiologyOncologyMolecular OncologyNeoplasiaOncogenesOncogenic VirusesProtein DegradationProteolytic EnzymesTumor Suppressor Gene InactivationTumor Suppressor GenesViral OncogenesisE7 ExpressionE7 OncoproteinHigh-risk Human Papillomavirus TypesMetabolic Half-lifeProteasomal TurnoverProteasome InhibitorsProteasome-mediated DegradationRetinoblastoma Family Proteins
The steady-state level and metabolic half-life of retinoblastoma tumor suppressor protein pRB are decreased in cells that express high-risk human papillomavirus (HPV) E7 proteins. Here we show that pRB degradation is a direct activity of E7 and does not reflect a property of cell lines acquired during the selection process for E7 expression. An amino-terminal domain of E7 that does not directly contribute to pRB binding but is required for transformation is also necessary for E7-mediated pRB degradation. Treatment with inhibitors of the 26S proteasome not only blocks E7-mediated pRB degradation but also causes the stabilization of E7. Mutagenic analyses, however, reveal that the processes of proteasomal degradation of E7 and pRB are not linked processes. HPV type 16 E7 also targets the pRB-related proteins p107 and p130 for destabilization by a proteasome-dependent mechanism. Using the SAOS2 flat-cell assay as a biological indicator for pRB function, we demonstrate that pRB degradation, not solely binding, is important for the E7-induced inactivation of pRB.
54
The Human Papilloma Virus-16 E7 Oncoprotein Is Able to Bind to the Retinoblastoma Gene Product
Nicholas J. Dyson, Peter M. Howley, Karl Münger et al. · Science · 1989 · 3.1K citations